WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
Condition(s):Epithelial Ovarian CancerLast Updated:May 17, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Epithelial Ovarian CancerLast Updated:May 17, 2023Recruiting
Condition(s):Ovarian Carcinoma; Breast CancerLast Updated:July 12, 2023Completed
Condition(s):Breast CancerLast Updated:January 29, 2024Active, not recruiting
Condition(s):Breast Cancer Metastatic; BRCA 1 Gene Mutation; BRCA 2 Gene MutationLast Updated:December 21, 2023Active, not recruiting
Condition(s):Non-small-cell Lung Cancer PatientsLast Updated:October 5, 2022Recruiting
Condition(s):Ovarian Cancer; Breast Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial CancerLast Updated:December 17, 2019Completed
Condition(s):Pulmonary Arterial HypertensionLast Updated:August 26, 2020Terminated
Condition(s):PSR Ovarian Cancer With a BRCA MutationLast Updated:May 17, 2018No longer available
Condition(s):Advanced Cancers Harbouring Mutations in HRGLast Updated:July 9, 2020Recruiting
Condition(s):Advanced Breast CancerLast Updated:February 22, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.